Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics is showing promise for future growth and profitability, despite a temporary increase in net losses due to a transition in their business model. The company's new sleep center model offers a non-invasive, cost-effective solution for patients with sleep-disordered breathing, potentially making it a preferred treatment option over traditional methods. With continued expansion of their channel and partnerships, Vivos has the potential to see increased revenue and market share in the coming years. However, there are potential risks to attaining their share price target, including financial risks and competition in the healthcare industry. Overall, Vivos has a positive outlook, but investors should monitor their financial performance and developments in the market closely.

Vivos Therapeutics is showing promising growth in gross margins, but there are concerns over its reliance on customized treatment plans and lack of visibility in revenue and margins. The company's need for additional capital raises also poses a risk, as current financing may not be sufficient for long-term operations and growth. These factors lead to a negative outlook for Vivos Therapeutics, with a lower 12-month price target of $3 due to a higher share count and uncertainties in revenue projections.